Commitments and Contingencies - Additional Information (Detail) $ in Thousands		3 Months Ended		6 Months Ended
	Apr. 05, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	[1]	Mar. 31, 2022 USD ($)
Loss Contingencies [Line Items]
Research and Development Expense		$ 144,282	$ 290,059	$ 306,921	$ 613,635
Year Two [Member] | Twist Bioscience Corporation [Member]
Loss Contingencies [Line Items]
Minimum purchase commitment in contract years							$ 13,000
Year Three [Member] | Twist Bioscience Corporation [Member]
Loss Contingencies [Line Items]
Minimum purchase commitment in contract years							16,000
Year Four [Member] | Twist Bioscience Corporation [Member]
Loss Contingencies [Line Items]
Minimum purchase commitment in contract years							$ 19,000
Asset Purchase Agreement [Member] | StrideBio [Member]
Loss Contingencies [Line Items]
Payments for Royalties		$ 0		0
Royalty Recived From License Or Sale Of a Product	40
Royalty Recived From Licensing Revenue	10
Asset Purchase Agreement [Member] | Common Class A [Member] | StrideBio [Member]
Loss Contingencies [Line Items]
Additional consideration	$ 7,500
Fair value of the assets				2,800
Payments for Royalties	$ 17,500
Common Stock [Member] | Asset Purchase Agreement [Member] | StrideBio [Member]
Loss Contingencies [Line Items]
Fair value of the assets				4,000
Research and Development Expense				400
Common Stock [Member] | Asset Purchase Agreement [Member] | Common Class A [Member] | StrideBio [Member]
Loss Contingencies [Line Items]
Research and Development Expense				$ 3,600

[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.